Trial Profile
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms PROMOTE
- 08 Feb 2024 Planned End Date changed from 30 Dec 2023 to 30 Jun 2024.
- 18 Feb 2023 Results (Between June 2013 and August 2015) assessing the prognostic value of 20 previously identified genes in patients metastatic castrate resistant prostate cancer, presented at the 2023 Genitourinary Cancers Symposium.
- 13 Feb 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.